Crossmark

Percutaneous Cryoablation of Stage T1b Renal Cell Carcinoma: Safety, Technical Results, and Clinical Outcomes

Crossref DOI link: https://doi.org/10.1007/s00270-019-02226-5

Published Online: 2019-05-01

Published Print: 2019-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gunn, Andrew J. https://orcid.org/0000-0001-9081-446X
Joe, Winston B.

Salei, Aliaksei

El Khudari, Husameddin

Mahmoud, Khalid H.

Bready, Eric

Keasler, Eric M.

Patten, Patrick P.

Gordetsky, Jennifer B.

Rais-Bahrami, Soroush

Abdel Aal, Ahmed K.
License Information

Text and Data Mining valid from 2019-05-01
More Information

Article History

Received: 29 January 2019

Accepted: 16 April 2019

First Online: 1 May 2019

Compliance with Ethical Standards

:

: Dr. Gunn is a consultant and speaker for BTG International, and Dr. Abdel Aal is a consultant for Abbott Laboratories, Baxter Intl., W.L. Gore & Associates, C.R. Bard Inc., Sirtex Medical, and Boston Scientific Corporation. None of the other authors report a potential conflict of interest associated with this work and there is no grant support associated with this work.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required. This study was approved by the Institutional Review Board (IRB) of the University of Alabama at Birmingham.

: This article does not contain any studies with animals performed by any of the authors.

: For this type of study informed consent is not required.